Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018-Reference-Cited by-同舟云学术

Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018

Published:2020-03-03 Issue:9 Volume:323 Page:854
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Hernandez Inmaculada¹²,San-Juan-Rodriguez Alvaro¹²,Good Chester B.²³⁴⁵,Gellad Walid F.²³⁵

Affiliation:

1. Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania

2. Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, Pennsylvania

3. Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

4. Insurance Services Division, UPMC Health Plan, Pittsburgh, Pennsylvania

5. VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2762310/jama_hernandez_2020_oi_200012.pdf

Reference25 articles.

1. The contribution of new product entry versus existing product inflation in the rising costs of drugs.;Hernandez;Health Aff (Millwood),2019

2. Trends in prices of popular brand-name prescription drugs in the United States.;Wineinger;JAMA Netw Open,2019

3. Price increases of protected-class drugs in Medicare Part D, relative to inflation, 2012-2017.;Hwang;JAMA,2019

4. Analysis of proposed Medicare Part B to Part D shift with associated changes in total spending and patient cost-sharing for prescription drugs.;Hwang;JAMA Intern Med,2019

5. Assessing the value of sarilumab monotherapy for adults with moderately to severely active rheumatoid arthritis: a cost-effectiveness analysis.;Whittington;J Manag Care Spec Pharm,2019

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Benefit and Revenues of Drugs Affected by Rare Pediatric Disease Priority Review Vouchers, 2017-2023;The Journal of Pediatrics;2024-12

2. Drug Shortage and Ethical Issues: Integrating Multidisciplinary Perspectives with a Shared Ethical Framework;Pharmacy;2024-09-06

3. Consumer Out-Of-Pocket Drug Prices Grew Faster Than Prices Faced By Insurers After Accounting For Rebates, 2007–20;Health Affairs;2024-09-01

4. State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization;Health Affairs;2024-08-01

5. Global outlook on affordability of biotherapeutic drugs;Annals of the New York Academy of Sciences;2024-06-13